(ARQT) Arcutis Biotherapeutics - Overview
Stock: Topical Cream, Topical Foam, JAK1 Inhibitor, JAK1 Cream
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 46.4% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.48 |
| Alpha | 90.16 |
| Character TTM | |
|---|---|
| Beta | 1.128 |
| Beta Downside | 1.105 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.26% |
| CAGR/Max DD | 0.20 |
Description: ARQT Arcutis Biotherapeutics January 15, 2026
Arcutis Biotherapeutics (ARQT) is a U.S.-based biotech focused on dermatology, developing topical and biologic candidates for conditions such as plaque psoriasis, atopic dermatitis, alopecia areata, hand eczema, vitiligo, and seborrheic dermatitis. Its lead asset, ZORYVE (roflumilast cream), is in late-stage trials for plaque psoriasis and atopic dermatitis, while a foam formulation (ARQ-154) targets scalp and body psoriasis.
Key pipeline highlights include: ARQ-255, a selective JAK1 inhibitor for alopecia areata; ARQ-252, a JAK1-selective topical cream for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein aimed at atopic dermatitis. The company, incorporated in 2016 and renamed in 2019, is headquartered in Westlake Village, California.
From a market-size perspective, the global dermatology therapeutics market is projected to exceed $30 billion by 2028, with topical treatments accounting for roughly 40 % of that spend-providing a sizable addressable pool for Arcutis’s products. As of the latest filing (Q3 2024), ARQT reported cash and equivalents of about $120 million, giving an estimated runway of 12–15 months assuming current burn rates, a critical KPI for funding upcoming Phase III readouts.
Recent sector dynamics show a shift toward small-molecule and topical therapies that can bypass injection-related adherence issues, a trend that underpins Arcutis’s strategic focus on cream/foam formulations and JAK1 selectivity, which may also mitigate safety concerns seen with broader JAK inhibitors.
If you want a data-rich, quantitative deep-dive on ARQT’s valuation assumptions, consider checking ValueRay’s analyst platform for the latest model inputs and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -44.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 28.06 > 1.0 |
| NWC/Revenue: 78.46% < 20% (prev 181.2%; Δ -102.7% < -1%) |
| CFO/TA -0.09 > 3% & CFO -32.6m > Net Income -44.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (132.9m) vs 12m ago 6.90% < -2% |
| Gross Margin: 89.96% > 18% (prev 0.90%; Δ 8907 % > 0.5%) |
| Asset Turnover: 78.66% > 50% (prev 31.72%; Δ 46.95% > 0%) |
| Interest Coverage Ratio: -1.96 > 6 (EBITDA TTM -24.0m / Interest Expense TTM 14.6m) |
Altman Z'' -11.92
| A: 0.67 (Total Current Assets 349.2m - Total Current Liabilities 99.8m) / Total Assets 371.0m |
| B: -3.11 (Retained Earnings -1.16b / Total Assets 371.0m) |
| C: -0.07 (EBIT TTM -28.7m / Avg Total Assets 404.2m) |
| D: -5.43 (Book Value of Equity -1.16b / Total Liabilities 212.9m) |
| Altman-Z'' Score: -11.92 = D |
Beneish M -1.79
| DSRI: 0.84 (Receivables 115.1m/60.1m, Revenue 317.9m/138.7m) |
| GMI: 1.00 (GM 89.96% / 89.57%) |
| AQI: 1.81 (AQ_t 0.04 / AQ_t-1 0.02) |
| SGI: 2.29 (Revenue 317.9m / 138.7m) |
| TATA: -0.03 (NI -44.3m - CFO -32.6m) / TA 371.0m) |
| Beneish M-Score: -1.79 (Cap -4..+1) = B |
What is the price of ARQT shares?
Over the past week, the price has changed by +7.69%, over one month by -6.50%, over three months by +8.84% and over the past year by +119.97%.
Is ARQT a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARQT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.8 | 16.2% |
| Analysts Target Price | 31.8 | 16.2% |
| ValueRay Target Price | 28.1 | 2.7% |
ARQT Fundamental Data Overview February 04, 2026
P/S = 9.8517
P/B = 19.6594
Revenue TTM = 317.9m USD
EBIT TTM = -28.7m USD
EBITDA TTM = -24.0m USD
Long Term Debt = 107.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.00m USD (from shortTermDebt, last quarter)
Debt = 113.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 66.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.05b USD (3.13b + Debt 113.8m - CCE 191.1m)
Interest Coverage Ratio = -1.96 (Ebit TTM -28.7m / Interest Expense TTM 14.6m)
EV/FCF = -79.88x (Enterprise Value 3.05b / FCF TTM -38.2m)
FCF Yield = -1.25% (FCF TTM -38.2m / Enterprise Value 3.05b)
FCF Margin = -12.03% (FCF TTM -38.2m / Revenue TTM 317.9m)
Net Margin = -13.94% (Net Income TTM -44.3m / Revenue TTM 317.9m)
Gross Margin = 89.96% ((Revenue TTM 317.9m - Cost of Revenue TTM 31.9m) / Revenue TTM)
Gross Margin QoQ = 91.25% (prev 90.81%)
Tobins Q-Ratio = 8.23 (Enterprise Value 3.05b / Total Assets 371.0m)
Interest Expense / Debt = 2.70% (Interest Expense 3.07m / Debt 113.8m)
Taxrate = 1.07% (80.0k / 7.49m)
NOPAT = -28.4m (EBIT -28.7m * (1 - 1.07%)) [loss with tax shield]
Current Ratio = 3.50 (Total Current Assets 349.2m / Total Current Liabilities 99.8m)
Debt / Equity = 0.72 (Debt 113.8m / totalStockholderEquity, last quarter 158.1m)
Debt / EBITDA = -2.78 (negative EBITDA) (Net Debt 66.7m / EBITDA -24.0m)
Debt / FCF = -1.74 (negative FCF - burning cash) (Net Debt 66.7m / FCF TTM -38.2m)
Total Stockholder Equity = 149.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.97% (Net Income -44.3m / Total Assets 371.0m)
RoE = -29.69% (Net Income TTM -44.3m / Total Stockholder Equity 149.3m)
RoCE = -11.16% (EBIT -28.7m / Capital Employed (Equity 149.3m + L.T.Debt 107.5m))
RoIC = -11.03% (negative operating profit) (NOPAT -28.4m / Invested Capital 257.2m)
WACC = 9.81% (E(3.13b)/V(3.25b) * Re(10.07%) + D(113.8m)/V(3.25b) * Rd(2.70%) * (1-Tc(0.01)))
Discount Rate = 10.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.81%
Fair Price DCF = unknown (Cash Flow -38.2m)
EPS Correlation: 94.43 | EPS CAGR: 42.04% | SUE: 0.89 | # QB: 1
Revenue Correlation: 95.42 | Revenue CAGR: 177.1% | SUE: 1.14 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=-0.006 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=0.46 | Chg30d=+0.007 | Revisions Net=+5 | Growth EPS=+433.3% | Growth Revenue=+30.3%